EA202090459A1 - METHODS FOR TREATMENT OF MALIGNANT TUMORS USING FARNESIL TRANSFERASE INHIBITORS - Google Patents

METHODS FOR TREATMENT OF MALIGNANT TUMORS USING FARNESIL TRANSFERASE INHIBITORS

Info

Publication number
EA202090459A1
EA202090459A1 EA202090459A EA202090459A EA202090459A1 EA 202090459 A1 EA202090459 A1 EA 202090459A1 EA 202090459 A EA202090459 A EA 202090459A EA 202090459 A EA202090459 A EA 202090459A EA 202090459 A1 EA202090459 A1 EA 202090459A1
Authority
EA
Eurasian Patent Office
Prior art keywords
blasts
bone marrow
methods
malignant tumors
treatment
Prior art date
Application number
EA202090459A
Other languages
Russian (ru)
Inventor
Антонио Гвальберто
Original Assignee
Кура Онколоджи, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Кура Онколоджи, Инк. filed Critical Кура Онколоджи, Инк.
Priority claimed from PCT/US2018/045478 external-priority patent/WO2019032489A1/en
Publication of EA202090459A1 publication Critical patent/EA202090459A1/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Настоящее изобретение относится к области терапии злокачественных опухолей. Конкретно, настоящее изобретение относится к способам лечения злокачественной опухоли у субъекта, имеющего клинические признаки хоминга в костном мозге миелоидных клеток, включая нейтропению, изолированную нейтропению, низкий процент бластов в периферической крови в присутствии или в отсутствие высокого процента бластов в костном мозге и/или низкое соотношение бластов в периферической крови и бластов в костном мозге с использованием ингибитора фарнезилтрансферазы (FTI), включающим определение того, является ли субъект, вероятно, способным отвечать на лечение FTI, на основании гематологических характеристик, указывающих на хоминг в костном мозге миелоидных клеток.The present invention relates to the field of therapy for malignant tumors. Specifically, the present invention relates to methods for treating cancer in a subject having clinical signs of myeloid cell homing in the bone marrow, including neutropenia, isolated neutropenia, a low percentage of blasts in peripheral blood in the presence or absence of a high percentage of blasts in the bone marrow, and / or low the ratio of peripheral blood blasts to bone marrow blasts using a farnesyl transferase inhibitor (FTI), comprising determining whether a subject is likely to respond to FTI treatment based on hematological characteristics indicative of myeloid cell homing in the bone marrow.

EA202090459A 2018-03-21 2018-08-07 METHODS FOR TREATMENT OF MALIGNANT TUMORS USING FARNESIL TRANSFERASE INHIBITORS EA202090459A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862646292P 2018-03-21 2018-03-21
PCT/US2018/045478 WO2019032489A1 (en) 2017-08-07 2018-08-07 Methods of treating cancer with farnesyltransferase inhibitors

Publications (1)

Publication Number Publication Date
EA202090459A1 true EA202090459A1 (en) 2020-09-29

Family

ID=72616019

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202090459A EA202090459A1 (en) 2018-03-21 2018-08-07 METHODS FOR TREATMENT OF MALIGNANT TUMORS USING FARNESIL TRANSFERASE INHIBITORS

Country Status (1)

Country Link
EA (1) EA202090459A1 (en)

Similar Documents

Publication Publication Date Title
EA201992220A1 (en) COMBINED THERAPY FOR TREATMENT OR PREVENTION OF TUMORS
EA201890009A1 (en) EZH2 INHIBITORS FOR TREATING LYMPHOMA
RU2014110228A (en) DIAGNOSTIC MARKERS
EP4085919A3 (en) Compositions and methods to treat cancer
PH12019501942A1 (en) Use of biomarkers in identifying cancer patients that will be responsive to treatment with a prmt5 inhibitor
EA201790502A1 (en) HYSTON DIMETHYLASE INHIBITORS
Kwon et al. Combinatorial effects of an epigenetic inhibitor and ionizing radiation contribute to targeted elimination of pancreatic cancer stem cell
MX2022016355A (en) Methods for delaying, preventing, and treating acquired resistance to ras inhibitors.
Suer et al. Characterization of stem-like cells directly isolated from freshly resected laryngeal squamous cell carcinoma specimens
MX2022010512A (en) Bcl-2 protein inhibitors.
MX2022014326A (en) Multispecific proteins.
El-Hadaad Immunohistochemical expression and prognostic relevance of Bmi-1, a stem cell factor, in epithelial ovarian cancer
ATE478076T1 (en) AZAXANTHONES FOR THE TREATMENT OF TUMORS
CL2020003204A1 (en) Treatment of stage iii nsclc and mitigation of pathological conditions associated with treatment
EA202190862A1 (en) METHODS OF TREATMENT
GB2523211A (en) MCT protein inhibitor-related prognostic and therapeutic methods
Gao et al. Knockdown of MPP8 suppresses cell proliferation via regulation of HOXA5 in non-small cell lung cancer cells
EA202090459A1 (en) METHODS FOR TREATMENT OF MALIGNANT TUMORS USING FARNESIL TRANSFERASE INHIBITORS
PH12020550042A1 (en) Methods of treating cancer with farnesyltransferase inhibitors
CY1111522T1 (en) 84P2A9: SPECIFIC TO PROTECTOR AND TYPES OF PROTEIN EXPRESSIVED IN HIGH PROTECTIVE CANCER
Yerlikaya Expression of heme oxygenase-1 in response to proteasomal inhibition
MX2021003265A (en) Treatment methods.
BR112022026247A2 (en) METHOD TO ENHANCE THE THERAPEUTIC EFFECTIVENESS OF AN IMMUNOTHERAPY AGENT, METHOD OF TREATMENT OF CANCER AND METHOD OF INHIBITING THE GROWTH OF A CANCER CELL
MX2021002882A (en) Targeting egln1 in cancer.
AR112674A1 (en) CANCER TREATMENT METHODS WITH FARNESILTRANSFERASE INHIBITORS